Ionis Pharmaceuticals (IONS) FCF Margin (2009 - 2026)

Ionis Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 205.06% for Q2 2026.

• In Q2 2026, FCF Margin rose 17430.0% year-over-year to 205.06%; the TTM figure through Jun 2026 stood at 82.72% (down 5200.0% YoY), while the FY2025 annual figure was 33.91%, up 4355.0% from the prior year.
• FCF Margin for Q2 2026 stood at 205.06%, up from 1629.16% in the prior quarter.
• The five-year high for FCF Margin was 205.06% in Q2 2026, with the low at 1629.16% in Q1 2026.
• The 5-year median for FCF Margin is 69.8% (2024), against an average of 136.24%.
• Peak annual rise in FCF Margin reached 17430 bps in 2026, while the deepest fall reached 150505 bps in 2026.
• Ionis Pharmaceuticals' FCF Margin stood at 134.53% in 2022, then soared by 108 bps to 10.38% in 2023, then plunged by 702 bps to 62.51% in 2024, then declined by 25 bps to 78.2% in 2025, then surged by 362 bps to 205.06% in 2026.
• Business Quant data shows IONS's FCF Margin at 205.06% in Q2 2026, 1629.16% in Q1 2026, and 78.2% in Q4 2025.